Clinical trials
Epilepsy trials in Portugal
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
46 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2002 | 4 |
| 2003 | 1 |
| 2004 | 5 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 2 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2014 | 1 |
| 2015 | 3 |
| 2018 | 4 |
| 2019 | 2 |
| 2020 | 2 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 5 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 34 |
| Terminated | 4 |
| Active, not recruiting | 3 |
| Enrolling by invitation | 3 |
| Recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bial - Portela C S.A. | 18 |
| UCB BIOSCIENCES, Inc. | 4 |
| Xenon Pharmaceuticals Inc. | 4 |
| Biohaven Therapeutics Ltd. | 3 |
| Longboard Pharmaceuticals | 3 |
| GlaxoSmithKline | 2 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2 |
| Takeda | 2 |
| UCB BIOSCIENCES GmbH | 2 |
| Eisai Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Epilepsy | 46 |
| Seizures | 19 |
| Epilepsies, Partial | 8 |
| Drug Resistant Epilepsy | 6 |
| Epilepsies, Myoclonic | 4 |
| Lennox Gastaut Syndrome | 4 |
| Neurodevelopmental Disorders | 3 |
| Brain Diseases | 1 |
| Central Nervous System Diseases | 1 |
| Epilepsy, Absence | 1 |
Trials
Showing 26 to 46 of 46. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.